Xiang Lu1, Ming Chang Hu2,3,4. 1. Department of Geriatrics, Sir Run Run Hospital, Nanjing Medical University, Nanjing, PR China. 2. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3. Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA. 4. Department of Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Abstract
BACKGROUND: Membrane αKlotho (hereinafter called Klotho) is highly expressed in the kidney and functions as a coreceptor of FGF receptors (FGFRs) to activate specific fibroblast growth factor 23 (FGF23) signal pathway. FGF23 is produced in bones and participates in the maintenance of mineral homeostasis. The extracellular domain of transmembrane Klotho can be cleaved by secretases and released into the circulation as soluble Klotho. Soluble Klotho does not only weakly activate FGFRs to transduce the FGF23 signaling pathway, but also functions as an enzyme and hormonal substance to play a variety of biological functions. FGF23 exerts its biological effects through activation of FGFRs in a Klotho-dependent manner. However, extremely high FGF23 can exert its pathological action in a Klotho-independent manner. SUMMARY: The decline in serum and urinary Klotho followed by a rise in serum FGF23 at an early stage of chronic kidney disease (CKD) functions as an early biomarker for kidney dysfunction and can also serve as a predictor for risk of cardiovascular disease (CVD) and mortality in both CKD patients and the general population. Moreover, Klotho deficiency is a pathogenic factor for CKD progression and CVD. FGF23 may also contribute to CVD. Prevention of Klotho decline, reactivation of endogenous Klotho production, or supplementation of exogenous Klotho attenuate renal fibrosis, retard CKD progression, improve mineral metabolism, ameliorate cardiomyopathy, and alleviate vascular calcification in CKD. However, the poor CVD outcome after depletion of FGF23 with FGF23 antibody stimulates the generation of a more specific inhibitor of FGF23 for CKD treatment. KEY MESSAGE: Klotho/FGF23 may not only be diagnostic and/or prognostic biomarkers for CKD and CVD, but are also pathogenic contributors to CKD progression and CVD development. The Klotho/FGF23 axis should be a novel target for renal clinics.
BACKGROUND: Membrane αKlotho (hereinafter called Klotho) is highly expressed in the kidney and functions as a coreceptor of FGF receptors (FGFRs) to activate specific fibroblast growth factor 23 (FGF23) signal pathway. FGF23 is produced in bones and participates in the maintenance of mineral homeostasis. The extracellular domain of transmembrane Klotho can be cleaved by secretases and released into the circulation as soluble Klotho. Soluble Klotho does not only weakly activate FGFRs to transduce the FGF23 signaling pathway, but also functions as an enzyme and hormonal substance to play a variety of biological functions. FGF23 exerts its biological effects through activation of FGFRs in a Klotho-dependent manner. However, extremely high FGF23 can exert its pathological action in a Klotho-independent manner. SUMMARY: The decline in serum and urinary Klotho followed by a rise in serum FGF23 at an early stage of chronic kidney disease (CKD) functions as an early biomarker for kidney dysfunction and can also serve as a predictor for risk of cardiovascular disease (CVD) and mortality in both CKD patients and the general population. Moreover, Klotho deficiency is a pathogenic factor for CKD progression and CVD. FGF23 may also contribute to CVD. Prevention of Klotho decline, reactivation of endogenous Klotho production, or supplementation of exogenous Klotho attenuate renal fibrosis, retard CKD progression, improve mineral metabolism, ameliorate cardiomyopathy, and alleviate vascular calcification in CKD. However, the poor CVD outcome after depletion of FGF23 with FGF23 antibody stimulates the generation of a more specific inhibitor of FGF23 for CKD treatment. KEY MESSAGE: Klotho/FGF23 may not only be diagnostic and/or prognostic biomarkers for CKD and CVD, but are also pathogenic contributors to CKD progression and CVD development. The Klotho/FGF23 axis should be a novel target for renal clinics.
Authors: N Koh; T Fujimori; S Nishiguchi; A Tamori; S Shiomi; T Nakatani; K Sugimura; T Kishimoto; S Kinoshita; T Kuroki; Y Nabeshima Journal: Biochem Biophys Res Commun Date: 2001-02-02 Impact factor: 3.575
Authors: Hyoung Rae Kim; Bo Young Nam; Dong Wook Kim; Min Woong Kang; Jae-Hyun Han; Mi Jung Lee; Dong Ho Shin; Fa Mee Doh; Hyang Mo Koo; Kwang Il Ko; Chan Ho Kim; Hyung Jung Oh; Tae-Hyun Yoo; Shin-Wook Kang; Dae Suk Han; Seung Hyeok Han Journal: Am J Kidney Dis Date: 2013-03-27 Impact factor: 8.860
Authors: Sarah Seiler; Kyrill S Rogacev; Heinz J Roth; Pagah Shafein; Insa Emrich; Stefan Neuhaus; Jürgen Floege; Danilo Fliser; Gunnar H Heine Journal: Clin J Am Soc Nephrol Date: 2014-03-27 Impact factor: 8.237
Authors: Ivana Pavik; Philippe Jaeger; Lena Ebner; Carsten A Wagner; Katja Petzold; Daniela Spichtig; Diane Poster; Rudolf P Wüthrich; Stefan Russmann; Andreas L Serra Journal: Nephrol Dial Transplant Date: 2012-11-04 Impact factor: 5.992
Authors: Jeroen P Kooman; Natascha J H Broers; Len Usvyat; Stephan Thijssen; Frank M van der Sande; Tom Cornelis; Nathan W Levin; Karel M L Leunissen; Peter Kotanko Journal: Nephrol Dial Transplant Date: 2012-11-08 Impact factor: 5.992
Authors: Xiaotian Zhong; Srinath Jagarlapudi; Yan Weng; Mellisa Ly; Jason C Rouse; Kim McClure; Tetsuya Ishino; Yan Zhang; Eric Sousa; Justin Cohen; Boriana Tzvetkova; Kaffa Cote; John J Scarcelli; Keith Johnson; Joe Palandra; James R Apgar; Suma Yaddanapudi; Romer A Gonzalez-Villalobos; Alan C Opsahl; Khetemenee Lam; Qing Yao; Weili Duan; Annette Sievers; Jing Zhou; Darren Ferguson; Aaron D'Antona; Richard Zollner; Hongli L Zhu; Ron Kriz; Laura Lin; Valerie Clerin Journal: J Biol Chem Date: 2020-01-31 Impact factor: 5.157